Literature DB >> 1612507

Management of endometrial adenocarcinoma with cervical involvement.

S C Rubin1, W J Hoskins, P E Saigo, D Nori, B Mychalczak, D Chapman, J L Lewis.   

Abstract

Seventy-seven patients with endometrial cancer with cervical involvement were treated at Memorial Sloan-Kettering Cancer Center from 1968 to 1982. Fractional curettage specimens showed that 25 patients (32%) had involvement of cervical stroma and 52 (68%) had only detached fragments of carcinoma present in endocervical curettings. Six patients treated for palliation only are excluded from analysis of treatment and survival. Our preferred treatment during the time interval studied consisted of preoperative whole pelvic radiotherapy followed by modified radical hysterectomy and bilateral salpingo-oophorectomy with post-operative intravaginal brachytherapy. This regimen was well tolerated by the 37 patients so treated. The remaining patients were treated with a variety of regimens, most commonly radiotherapy and simple hysterectomy (25 patients). With a mean follow-up among survivors of 97 months, disease-free survival is 72%. Mean time to relapse was 19 months, with 90% of relapses occurring within 40 months. Initial sites of relapse included abdomen, 9 (12.6%); lungs, 8 (11.3%); brain, 2 (2.8%); lateral pelvis, 2 (2.8%); and bone, 1 (1.4%). Clinicopathologic variables significantly related to risk of relapse included presence of extrauterine disease at surgery (P = 0.0001), extent of cervical involvement as determined prior to hysterectomy (P = 0.001), depth of myometrial invasion (P = 0.005), and papillary serous histology (P = 0.0002). Treatment of endometrial cancer with cervical involvement with combinations of radiotherapy and surgery is well tolerated and results in an excellent long-term disease-free survival and a low rate of pelvic relapse.

Entities:  

Mesh:

Year:  1992        PMID: 1612507     DOI: 10.1016/0090-8258(92)90307-5

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.

Authors:  Stella Capriglione; Francesco Plotti; Andrea Miranda; Roberto Ricciardi; Giuseppe Scaletta; Alessia Aloisi; Federica Guzzo; Roberto Montera; Roberto Angioli
Journal:  Tumour Biol       Date:  2015-01-11

2.  Recurrence patterns and complications in endometrial adenocarcinoma with cervical involvement.

Authors:  M P Boente; Y A Orandi; E L Yordan; A Miller; J E Graham; C Kirshner; G D Wilbanks
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

3.  Blood Vessel Invasion in Endometrial Cancer Is One of the Mechanisms of Spread to the Cervix.

Authors:  Gunsu Kimyon Comert; Derman Basaran; Hayriye Ergin Akkoz; Burcin Celik; Selcan Sinaci; Osman Turkmen; Alper Karalok; Olcay Kandemir; Taner Turan
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

4.  Postoperative surgical complications of lymphadenohysterocolpectomy.

Authors:  F Marin; M Pleşca; C I Bordea; S C Voinea; I Burlănescu; E Ichim; C G Jianu; R R Nicolăescu; M P Teodosie; K Maher; A Blidaru
Journal:  J Med Life       Date:  2014-03-25

5.  Efficacy of endocervical curettage and CA-125 measurement in endometrial serous carcinoma: A case series and literature review.

Authors:  Ahmet Cem İyibozkurt; Murat Doğan; Ercan Baştu; Hamdullah Sözen; Doğan Vatansever; Samet Topuz; Sinan Berkman
Journal:  Turk J Obstet Gynecol       Date:  2015-09-15

6.  MR staging in carcinoma of the endometrium and carcinoma of the cervix.

Authors:  M V Pakkal; V Rudralingam; W G McCluggage; B E Kelly
Journal:  Ulster Med J       Date:  2004-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.